2023-05-31 09:14:48 ET
- Evaxion Biotech ADS press release ( EVAX ): Q1 GAAP EPS of -$0.24.
- Cash position: As of March 31, 2023, cash and cash equivalents were $10.2 million as compared to $13.2 as of December 31, 2022.
- Research and Development expenses were $3.9 million for the quarter ended March 31, 2023 as compared to $4.8 million for the quarter ended March 31, 2022.
- General and Administrative expenses were $2.5 million for the quarter ended March 31, 2023 as compared to $1.6 million for the quarter ended March 31, 2022.
For further details see:
Evaxion Biotech ADS GAAP EPS of -$0.24